IFN-γ Facilitates Release of Class II-Loaded Intracellular Pools in Trophoblast Cells: A Novel Property Independent of Protein Synthesis (original) (raw)

Abstract

Interferon-c (IFN-c) is an abortion-inducing factor, yet its effects in such a reaction are subject to various levels of regulation. The trophoblast cell line TROPHO-1 can be induced by IFN-c to express mRNA and surface class II major histocompatibility complex (MHC) proteins after 8 and 48 h of stimulation, respectively. Untreated cells, however, show an intracellular accumulation of class II antigens earlier (6 h), indicating the existence of MHC pools in the cystosol independent of any induction. On addition of IFN-c , immunofluorescence, subcellular fractionation, and ELISA experiments showed that class II antigen activity detected in the endosomal compartments of the cells could be measured in the culture supernatants. These soluble class II proteins, when isolated and purified using magnetic bead isolation techniques and tested in SDS-PAGE gel and Western blot experiments, had a molecular weight of 70 kDa. Administration of these molecules to pregnant mice as culture supernatants increased the abortion rate and decreased maternal hematocrit levels, effects that could be immunoabsorbed by anti-I-A d monoclonal antibodies (mAb). These results indicate that although surface class II molecules are not expressed on trophoblast cells, they accumulate in endosomal compartments and can be released from the cells on addition of IFN-c. This new IFN-c property, to mobilize intracellular pools of class II MHC antigens in trophoblast cells independent of de novo protein synthesis and induce their release to the extracellular matrix, is a mechanism that appears to be involved in the fetal rejection process, facilitating priming of the maternal organism against the fetal allograft.

Loading...

Loading Preview

Sorry, preview is currently unavailable. You can download the paper by clicking the button above.

References (29)

  1. BALKWILL, F.R. (1979). Interferons as cell regulatory molecules. Cancer Immunol. Immunopathol. 7, 7-14.
  2. EPSTAIN, L. (1981). Interferon-gamma: is it really different? In- terferon 3, 13-44.
  3. ALBANESI, C., CAVANI, A., and GIROLOMONI, G. (1998). In- terferon-gamma-stimulated human keratinocytes express the genes necessary for the production of peptide-loaded MHC class II mol- ecules. J. Invest. Dermatol. 110, 138-142.
  4. CATALFAMO, M., SERRADELL, L., ROURA-MIR, C., KOLKOWSKI, E., SOSPEDRA, M., VIVES-PI, M., VARGAS- NIETO, F., PUJOL-BORRELL, R., and JARAQUEMADA, D. (1999). HLA-DM and invariant chain are expressed by thyroid fol- licular cells, enabling the expression of compact DR molecules. Int. Immunol. 11, 269-277.
  5. ATHANASSAKIS, I., AIFANTIS, Y., MAKRYGIANNAKIS, A., KOUMANTAKIS, E., and VASSILIADIS, S. (1995). Placental tis- sue from human miscarriages expresses class II HLA-DR antigens. Am. J. Reprod. Immunol. 34, 281-287.
  6. VASSILIADIS, S., TSOUKATOS, D., and ATHANASSAKIS, I. (1994). Interferon-induced class II expression on the spongiotro- phoblastic zone of the murine placenta is linked to fetal rejection and developmental abnormalities. Acta Physiol. Scand. 151, 485-495.
  7. ATHANASSAKIS-VASSILIADIS, I., THANOS, D., and PAPA- MATHEAKIS, J. (1989). Induction of class II major histocompat- ibility complex antigens in the murine placenta by 5-azacitidine and interferon-h involves different cell populations. Eur. J. Im- munol. 19, 2341-2348.
  8. ATHANASSAKIS, I., and VASSILIADIS, S. (1995). Effect of IFN-g administration in virgin and pregnant mice: distribution of lymphoid and myeloid cells in the spleen. Eur. Cytokine Netw. 6, 167-176.
  9. ATHANASSAKIS, I., AIFANTIS, Y., RANELLA, A., and VAS- SILIADIS, S. (1996). Production of embryotoxic IgG antibodies during IFN-g treatment of pregnant mice. Am. J. Reprod. Immunol. 36, 111-117.
  10. ATHANASSAKIS, I. (1999). Cytokine/hormonal production, re- sponsiveness to growth factors and MHC inducibility of the murine trophoblast cell line TROPHO-1. Trophoblast Res. 13, 55-67.
  11. QIU, Y., XU, X., WANDINGER-NESS, A., DALKE, D.P., and PIERCE, S.K. (1994). Separation of subcellular compartments con- taining distinct functional forms of MHC class II. J. Cell Biol. 125, 595-605.
  12. ATHANASSAKIS, I., and ICONOMIDOU, B. (1996). Cytokine production in the serum and spleen of mice from day 6 to 14 of gestation. Dev. Immunol. 4, 247-255.
  13. DYNAL TECHNICAL HANDBOOK. Magnetic protein purifica- tion using Dynabeads. In: Cell Separation and Protein Purifica- tion, 2nd ed. A.S. Dynal (ed.) Oslo, Norway: Dynal, pp. 118-150.
  14. LAEMMLI, U.K. (1970). Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 277, 680-685.
  15. HEUKESHOVEN, J., and DERNICK, R. (1988). Improved silver staining procedure for fast staining in PhastSystem development unit. I. Staining of sodium dodesyl sulfate gels. Electrophoresis 9, 28-32.
  16. CHAOUAT, G., MENU, E., BUSTANY, P., REBUT-BON- NETON, C., SZEKERES-BARTHO, J., and WEGMANN, T.G. (1988). Role du placenta dans le maintien de l'allogreffe fetale. Re- prod. Nutr. Dev. 28, 1587-1588 (in French).
  17. VASSILIADIS, S., and ATHANASSAKIS, I. (1992). Type II in- terferon may be a potential hazardous therapeutic agent during pregnancy. Br. J. Haematol. 82, 782-783.
  18. ISAAZ, S., BAETZ, K., OLSEN, K., PODACK, E., and GRIF- FITHS, G.M. (1995). Serial killing by cytotoxic T lymphocytes: T cell receptor triggers degranulation, refilling of the lytic granules and secretion of lytic proteins via a non-granule pathway. Eur. J. Immunol. 25, 1071-1079.
  19. SUMIMOTO, R., and KAMADA, N. (1990). Specific suppression of allograft rejection by soluble class I antigen and complexes with monoclonal antibodies. Transplantation. 50, 678-682.
  20. FUJII, T., ISHITANI, A., and GERAGHTY, D.E. (1994). A solu- ble form of the HLA-G antigen is encoded by a messenger ri- bonucleic acid containing intron 4. J. Immunol. 153, 5516-5524.
  21. WEYAND, C.M., JENDRO, M., and GORONZY, J.J. (1991). Sol- uble HLA-DR molecules in patients with HLA class II versus class I associated disorders. Autoimmunity 8, 281-287.
  22. JENDRO, M., GORONZY, J.J., and WEYAND, C.M. (1991). Structural and functional characterization of HLA-DR molecules circulating in the serum. Autoimmunity 8, 289-296.
  23. OTT, M., SEIDL, C., WESTHOFF, U., STECKER, K., SEIFRIED, E., FISCHER, P.A., and GROSSE-WILDE, H. (1998). Soluble HLA class I and class II antigens in patients with multiple sclero- sis. Tissue Antigens 51, 301-304.
  24. FILACI, G., CONTINI, P., BRENCI, S., LANZA, L., SCU- DELETTI, M., INDIVERI, F., and PUPPO, F. (1995). Increased serum concentration of soluble HLA-DR antigens in HIV infection and following transplantation. Tissue Antigens 46, 117-123.
  25. ATHANASSAKIS, I., PAFLIS, M., RANELLA, A., and VAS- SILIADIS, S. (1999). Detection of soluble HLA-G levels in ma- ternal serum can be predictive for a successful pregnancy. Trans- plant. Proc. 31, 1834-1837.
  26. FAIRCHILD, P.J., and WRAITH, D.C. (1996). Lowering the tone: mechanisms of immunodominance among epitopes with low affin- ity for MHC. Immunol. Today 17, 80-85.
  27. ROGERS, P.R., GREY, H.M., and CROFT, M. (1998). Modulation of naive CD4 T cell activation with altered peptide ligands: the na- ture of the peptide and presentation in the context of co-stimulation are critical for sustained response. J. Immunol. 160, 3698-3704.
  28. RAPOSO, G., NIJMAN, H.W., STOORVOGEL, W., LIEJEN- DEKKER, R., HARDING, C.V., MELIEF, C.J., and GEUZE, H.J. (1996). B lymphocytes secrete antigen-presenting vesicles. J. Exp. Med. 183, 1161-1172.
  29. BUSCH, R., DOEBELE, R.C., PATIL, S., PASHINE, A., and MELLINS, E.D. (2000). Accessory molecules for MHC class II peptide loading. Curr. Opin. Immunol. 12, 99-106.